Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry in Breast Cancer
Authors:
- Sophie LabergeSLSophie Laberge
- Chantal CaronCCChantal Caron
- Louise ProvencherLPLouise Provencher
- Jean-Charles HogueJHJean-Charles Hogue
- François SanschagrinFSFrançois Sanschagrin
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 22 (8) , 613-618
Abstract
Estrogen receptor (ER) tumor's status is critical for breast cancer management. A new rabbit antibody clone, EP1, is now available for ER status determination. The objective was to validate the EP1 antibody clone for its use in breast cancer ER status determination in a clinical setting against the previous standard, SP1. EP1 clone was assessed in 130 consecutive cases, including 50 ER-negative (<1% ER expression), 13 ER-low-positive (1% to 9% ER expression), and 67 ER-positive (≥10% ER expression). Using EP1 versus SP1, positive agreement (sensibility) was 92.5% and negative agreement (specificity) was 100%, leading to an overall agreement of 95.4%. All discordant cases (n=6) were ER-low-positive. SP1 was remeasured in 13 ER-low-positive and in 11 ER-negative cases. Overall agreement between SP1 initial tumor status and reassessment was 70.8% in those negative and low-positive cases. In conclusion, EP1 antibody has been validated for use in breast cancer with a positive agreement ≥90% and a negative agreement ≥95%, as recommended. Also, overall agreement between EP1 and SP1 was as good as between the SP1 initial status and SP1 reassessment.Keywords
This publication has 28 references indexed in Scilit:
- Antibody validationBioTechniques, 2010
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk ReductionJournal of Clinical Oncology, 2009
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting SurvivalJournal of Clinical Oncology, 2006
- Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction AssaysJNCI: Journal of the National Cancer Institute, 2006
- Hormone receptor status and survival in a population‐based cohort of patients with breast carcinomaCancer, 2005
- How To Use Prognostic Factors in Axillary Node-Negative Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 1990
- Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand bindingJournal of Clinical Laboratory Analysis, 1990
- Estrogen receptor status as a prognostic indicator for stage I breast cancer patientsBreast Cancer Research and Treatment, 1982
- Estrogen Receptors in Human Breast CancerJournal of Clinical Investigation, 1973